275 related articles for article (PubMed ID: 26336595)
21. Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension.
Schikowski EM; Swabe G; Chan SY; Magnani JW
J Am Heart Assoc; 2022 Nov; 11(22):e026620. PubMed ID: 36370005
[TBL] [Abstract][Full Text] [Related]
22. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension.
Swisher JW; Elliott D
Respir Med Case Rep; 2017; 20():45-47. PubMed ID: 27942445
[TBL] [Abstract][Full Text] [Related]
24. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Wu S; Hoang HB; Yang JZ; Papamatheakis DG; Poch DS; Alotaibi M; Lombardi S; Rodriguez C; Kim NH; Fernandes TM
Chest; 2022 Dec; 162(6):1360-1372. PubMed ID: 35841932
[TBL] [Abstract][Full Text] [Related]
25. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
26. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
Sulica R; Fenton R; Cefali F
Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
[TBL] [Abstract][Full Text] [Related]
27. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
28. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
30. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.
Domingo LT; Ivy DD; Abman SH; Grenolds AM; MacLean JT; Breaux JA; Minford KJ; Frank BS
Front Pediatr; 2022; 10():1014922. PubMed ID: 36533232
[TBL] [Abstract][Full Text] [Related]
31. Macitentan in the treatment of pulmonary arterial hypertension.
Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T
Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463
[TBL] [Abstract][Full Text] [Related]
32. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
33. The role of riociguat in combination therapies for pulmonary arterial hypertension.
Rahaghi FF; Trivieri MG; Sahay S
Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
[TBL] [Abstract][Full Text] [Related]
34. Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations.
Lombardi S; Kingman M; Duncan M; Berngard SC; Fernandes T
Respir Med; 2018 Oct; 143():139-146. PubMed ID: 30261985
[TBL] [Abstract][Full Text] [Related]
35. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
Raina A; Benza RL; Farber HW
Pulm Circ; 2017; 7(3):741-746. PubMed ID: 28671485
[TBL] [Abstract][Full Text] [Related]
36. Treatment of pulmonary hypertension.
Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
[TBL] [Abstract][Full Text] [Related]
37. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
[TBL] [Abstract][Full Text] [Related]
38. Management of Pulmonary Arterial Hypertension.
Weatherald J; Varughese RA; Liu J; Humbert M
Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
[TBL] [Abstract][Full Text] [Related]
39. Novel strategies for treatment of pulmonary arterial hypertension.
Jasińska-Stroschein M; Orszulak-Michalak D
Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
[TBL] [Abstract][Full Text] [Related]
40. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
